Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Express Scripts
Covington
Accenture
Dow
US Army
Federal Trade Commission
Chubb
Queensland Health

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,041,319

« Back to Dashboard

Which drugs does patent 7,041,319 protect, and when does it expire?


Patent 7,041,319 protects TRICOR and is included in two NDAs. There have been two Paragraph IV challenges on Tricor.

This patent has eighty-three patent family members in thirty-six countries.

Summary for Patent: 7,041,319

Title:Fenofibrate pharmaceutical composition having high bioavailabilty
Abstract:The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.
Inventor(s): Stamm; Andre (Griesheim, FR), Seth; Pawan (Irvine, CA)
Assignee: Laboratoires Fournier (Dijon, FR)
Application Number:10/290,333
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 2001DISCNYesNo► Subscribe► SubscribeY
Abbvie Inc
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 2001DISCNYesNo► Subscribe► SubscribeY
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-001Nov 5, 2004ABRXYesNo► Subscribe► SubscribeY
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,041,319

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,652,881 Fenofibrate pharmaceutical composition having high bioavailability► Subscribe
6,074,670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,343,540Process for producing fenofibrate tablets► Subscribe
6,589,552 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
7,037,529Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
6,277,405 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,329,214Process for producing fenofibrate tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,041,319

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine61096► Subscribe
Turkey9901660► Subscribe
TunisiaSN98009► Subscribe
Slovakia285847► Subscribe
Slovakia96299► Subscribe
Russian Federation2238089► Subscribe
Russian Federation2236850► Subscribe
Russian Federation2002109746► Subscribe
Russian Federation2196580► Subscribe
Portugal2050445► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
Healthtrust
Julphar
Merck
UBS
Johnson and Johnson
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot